These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 15807174

  • 1. [Treatment of chronic hepatitis B].
    Dybowska D, Pilarczyk M.
    Przegl Epidemiol; 2004; 58 Suppl 1():139-43. PubMed ID: 15807174
    [Abstract] [Full Text] [Related]

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.
    Antivir Ther; 2008 Nov; 13(4):571-9. PubMed ID: 18672536
    [Abstract] [Full Text] [Related]

  • 4. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B.
    Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Batur Y.
    Antivir Ther; 2004 Jun; 9(3):325-34. PubMed ID: 15259895
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
    Lu WL, Xie DY, Yao JL, Yao GB, Cui ZY, Zhang DF, Wu L.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW, Choi JY, Bae SH, Yoon SK, Kim CW, Nam SW, Lee CD, Lee YS, Cha SB, Chung KW.
    J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [The HBeAg/antiHBe seroconversion as a result of lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy].
    Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M.
    Pol Merkur Lekarski; 2004 Jun; 16(96):557-9. PubMed ID: 15510896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.